article thumbnail

New manufacturing facility could drive gold standard in cell therapy

European Pharmaceutical Review

A new Denmark-based manufacturing facility is set to establish the final development steps and upscaling of cell therapies. Partly due to this and due to the explorative phase cell therapy is in, it is very expensive to develop and manufacture cell therapies, so there simply are not many facilities doing it.”

article thumbnail

AstraZeneca to boost cell therapy operations with $300m manufacturing investment

European Pharmaceutical Review

AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. Currently, AstraZeneca’s manufacturing sites in the US focus on producing small molecules and biologics, the company highlighted.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Simplify, standardise, digitalise to transform manufacturing

European Pharmaceutical Review

Our ambition is to build a modern, industry-leading manufacturing network, by bringing together talented people and cutting-edge processes, technologies and data to reliably deliver high quality, affordable and sustainable medicines and vaccines to patients. Standardise manufacturing .

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

Sandoz to boost biosimilar development with manufacturing expansion

European Pharmaceutical Review

Sandoz has announced it is investing €25 million in its manufacturing site in Holzkirchen, Germany, to expand its biosimilar development capabilities. The investment “strengthens Bavaria’s position as a leading biotechnology hub” and will help to generate “innovation and job growth” noted Bavarian Prime Minister Dr Markus Söder.

article thumbnail

Bristol Myers Squibb boosts CAR T therapy manufacturing capabilities

European Pharmaceutical Review

After agreeing to acquire a US-based manufacturing facility and its operations from Novartis, Bristol Myers Squibb (BMS) adds in-house production of viral vectors to its capabilities. This move will support the expansion of the company’s global cell therapy manufacturing network.

article thumbnail

UK medicines manufacturing must remain domestic

European Pharmaceutical Review

To be a superpower globally, the UK life sciences sector must not only discover and develop medicines of the future domestically, but also manufacture a significant share in the country too, according to a new report from the Medicines Manufacturing Industry Partnership (MMIP). It provides almost 45 percent of the £36.9